Alexion Pharmaceuticals Takes on Amyloidosis with Caelum Biosciences
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 2 (Table of Contents)
Published: 14 Feb-2019
DOI: 10.3833/pdr.v2019.i2.2407 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In its first foray in treating light chain (AL) amyloidosis, Alexion Pharmaceuticals has purchased an equity stake in Caelum Biosciences and gained an option to acquire the company based on Phase II data for Caelum’s lead asset, CAEL-101...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS